← All trials
NCT05246878
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 28, 2022
- Primary completion
- Jul 20, 2022
- Completion date
- Jul 20, 2022
- First posted
- Feb 18, 2022
- Last posted
- Aug 19, 2022
- Enrollment
- 72
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Enanta PharmaceuticalsLead sponsor
- Enanta PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.